|
시장보고서
상품코드
1457962
세계의 줄기세포 치료 시장 : 시장 규모, 점유율 분석, 산업 수요 예측(-2030년)Stem Cell Therapy Market Size and Share Analysis by Type, Cell Source, Application - Global Industry Demand Forecast to 2030 |
||||||
세계의 줄기세포 치료(Stem Cell Therapy) 시장 규모는 2023년에는 3억 610만 달러였으며, 2030년에는 9억 1,080만 달러에 달할 것으로 예상됩니다.
성장 촉진 요인
시장 성장의 주요 요인은 정형외과 질환, 외상 및 신경 질환,자가 면역 질환(루푸스, 다발성 경화증, COPD, 뇌졸중, 파킨슨 병, ALS 등)의 이환율 증가입니다.
또한 줄기세포 치료에 대한 관심이 높아짐에 따라 줄기세포은행에 대한 요구도 높아지고 있어 미래 시장 확대의 원동력이 될 것으로 보입니다.
또한 연구의 진전이나 주문제약에 대한 주목이 높아지고 있는 것도 향후 몇 년간의 업계의 원동력이 될 것으로 보입니다.
동종 줄기 세포 치료가 가장 큰 점유율
2023년에는 동종 줄기세포 치료가 60%의 최대 점유율을 차지하고, 2024년부터 2030년에 걸쳐서는 17%의 속도로 증가할 것으로 예상됩니다.
이는 이러한 유형의 치료를 진행하기 위한 임상시험의 수가 증가하고 있기 때문입니다.
동종 이식의 가장 큰 장점은 이식편에 혼입하는 종양 세포가 없다는 것입니다. 이식편은 또한 기증자로부터 얻은 면역 담당 세포로 구성되며 면역이식편 대 악성 종양 효과를 시작할 수 있습니다.
북미가 가장 큰 수익 점유율을 차지
북미는 2023년 시점에서 55%의 점유율을 차지하고, 지역별로 시장의 리더가 되어 10년간의 분석 기간 말에 크게 성장할 것으로 보입니다.
이는 이 지역에서 줄기세포 치료의 개발에 투자가 이루어지고 있기 때문입니다.
아시아 태평양이 가장 급성장
아시아 태평양은 가장 급성장하고 있으며, 그 중에서도 중국은 줄기세포 치료에 주력하고 있는 중요한 나라입니다.
세계의 줄기세포 치료 시장에 대해 분석했으며, 시장의 기본 구조/최신 정세/주요 촉진·억제 요인/세계 전체 및 지역별·주요 국가별 시장 규모 동향 전망(금액 기준, 2017-2030년)/유형별·세포 공급원별·용도별 상세 동향/현재 시장 경쟁 상황/주요 기업 프로파일 등 정보를 전해드립니다.
목차
제1장 조사 범위
제2장 조사 방법
제3장 주요 요약
제4장 시장 지표
제5장 산업 전망
- 시장 역학
- 동향
- 성장 촉진 요인
- 억제 요인/과제
- 성장 촉진 요인/억제 요인의 영향 분석
- COVID-19의 영향
- Porter's Five Forces 분석
제6장 시장
- 개요
- 시장 매출 : 유형별(2017-2030년)
- 시장 매출 : 세포 공급원별(2017-2030년)
- 시장 매출 : 용도별(2017-2030년)
- 시장 매출 : 지역별(2017-2030년)
제7장 북미 시장
- 개요
- 시장 매출 : 유형별(2017-2030년)
- 시장 매출 : 세포 공급원별(2017-2030년)
- 시장 매출 : 용도별(2017-2030년)
- 시장 매출 : 국가별(2017-2030년)
제8장 유럽 시장
제9장 아시아 태평양 시장
제10장 남미 시장
제11장 중동 및 아프리카(MEA) 시장
제12장 미국 시장
- 개요
- 시장 매출 : 유형별(2017-2030년)
- 시장 매출 : 세포 공급원별(2017-2030년)
- 시장 매출 : 용도별(2017-2030년)
제13장 캐나다 시장
제14장 독일 시장
제15장 프랑스 시장
제16장 영국 시장
제17장 이탈리아 시장
제18장 스페인 시장
제19장 일본 시장
제20장 중국 시장
제21장 인도 시장
제22장 호주 시장
제23장 한국 시장
제24장 브라질 시장
제25장 멕시코 시장
제26장 사우디아라비아 시장
제27장 남아프리카 시장
제28장 아랍에미리트(UAE) 시장
제29장 경쟁 구도
- 시장 진출기업 및 제공 제품 및 서비스 목록
- 주요 기업의 경쟁 벤치마킹
- 주요 기업의 제품 벤치마킹
- 최근의 전략 전개 상황
제30장 기업 프로파일
- Smith&Nephew plc
- MEDIPOST Co. Ltd.
- Anterogen Co. Ltd.
- CORESTEM Inc.
- PHARMICELL Co. Ltd.
- NuVasive Inc.
- RTI Surgical Inc.
- AlloSource
- JCR Pharmaceutical Co. Ltd.
- Takeda Pharmaceutical Company Limited
제31장 부록
LYJ 24.04.16The size of the stem cell therapy market was USD 306.1 million in 2023, and it will touch USD 910.8 million in 2030, with a rate of 16.9% throughout the projection period.
Growth Drivers
The key factors responsible for the advance of the market are the growing incidence of orthopedic conditions, traumatic injuries, neurological ailments, and autoimmune diseases, such as lupus, multiple sclerosis, COPD, stroke, Parkinson's disease, and ALS.
Also, with the growing familiarity of stem cell therapy, the rising requirement for stem cell banking will power the market in the future.
Moreover, the growing advances in research and a rising emphasis on customized medications will power the industry in the years to come as well.
For example, in November 2022, USD 8 million was invested by the California Institute for Regenerative Medicine in the UC San Diego Alpha Stem Cell Clinic for allowing the latter to create more-efficient stem cell therapies for the diseases, which are difficult to treat.
Allogeneic Stem Cell Therapy had the Largest Share
The largest share of 60% was held by the Allogeneic stem cell therapy in 2023, and it will power at a rate of 17% during 2024-2030.
This is because of the growth in the count of clinical trials for the advance of these kinds of treatments.
The foremost advantage of allogeneic transplantation is that there is not any contaminating tumor cell in the graft. The graft also comprises immunocompetent cells resultant from a donor, which might initiate an immune graft-against-malignancy effect.
Autologous Therapy To Grow Significantly
The autologous therapy category will have a significant growth in the future due to the little risk of rejection of graft in this treatment. People requiring high-dose of chemotherapy and radiation are frequently transplanted with autologous stem cells for replacing the bone marrow damaged by the main treatment.
Furthermore, more than a few studies, conducted in recent times are focusing on autologous HSCT have shown optimistic results for secondary progressive multiple sclerosis. The method makes use of healthy blood stem cells from the own body of a person for replacing diseased cells.
North America to have Largest Revenue Share
North America was the leader of the regional market, with a share of 55%, in 2023, and it will grow significantly by the end of this decade.
This is due to the investment being provided for the development of stem cell therapies in this region.
For example, in September 2022, a gene-therapy-focused contract development and manufacturing company Forge Biologics Inc, publicized that it has acquired a total amount of USD 90 million in a Series C financing round co-led by Drive Capital and Aisling Capital, with another unrevealed strategic investor.
APAC Region To Grow the Fastest
Ther APAC region is observing the fastest-growth, with China being a key nation concentrating on stem cell therapy.
For example, OBiO Technology Corp. Ltd., a Shanghai-based gene-and-cell-therapy-focused CRO and CDMO in January 2023, publicized that the FDA has acknowledged its GMP plasmid drug master file filings for autologous and allogenic cell therapy and stem cell therapy products and helps in reducing the time taken in communication, assessment, and analysis of the filings for related therapeutics on part of the FDA.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by type
- 1.4.2. Market size breakdown, by cell source
- 1.4.3. Market size breakdown, by application
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Type (2017-2030)
- 6.3. Market Revenue, by Cell Source (2017-2030)
- 6.4. Market Revenue, by Application (2017-2030)
- 6.5. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Type (2017-2030)
- 7.3. Market Revenue, by Cell Source (2017-2030)
- 7.4. Market Revenue, by Application (2017-2030)
- 7.5. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Type (2017-2030)
- 8.3. Market Revenue, by Cell Source (2017-2030)
- 8.4. Market Revenue, by Application (2017-2030)
- 8.5. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Type (2017-2030)
- 9.3. Market Revenue, by Cell Source (2017-2030)
- 9.4. Market Revenue, by Application (2017-2030)
- 9.5. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Type (2017-2030)
- 10.3. Market Revenue, by Cell Source (2017-2030)
- 10.4. Market Revenue, by Application (2017-2030)
- 10.5. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Type (2017-2030)
- 11.3. Market Revenue, by Cell Source (2017-2030)
- 11.4. Market Revenue, by Application (2017-2030)
- 11.5. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Type (2017-2030)
- 12.3. Market Revenue, by Cell Source (2017-2030)
- 12.4. Market Revenue, by Application (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Type (2017-2030)
- 13.3. Market Revenue, by Cell Source (2017-2030)
- 13.4. Market Revenue, by Application (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Type (2017-2030)
- 14.3. Market Revenue, by Cell Source (2017-2030)
- 14.4. Market Revenue, by Application (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Type (2017-2030)
- 15.3. Market Revenue, by Cell Source (2017-2030)
- 15.4. Market Revenue, by Application (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Type (2017-2030)
- 16.3. Market Revenue, by Cell Source (2017-2030)
- 16.4. Market Revenue, by Application (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Type (2017-2030)
- 17.3. Market Revenue, by Cell Source (2017-2030)
- 17.4. Market Revenue, by Application (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Type (2017-2030)
- 18.3. Market Revenue, by Cell Source (2017-2030)
- 18.4. Market Revenue, by Application (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Type (2017-2030)
- 19.3. Market Revenue, by Cell Source (2017-2030)
- 19.4. Market Revenue, by Application (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Type (2017-2030)
- 20.3. Market Revenue, by Cell Source (2017-2030)
- 20.4. Market Revenue, by Application (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Type (2017-2030)
- 21.3. Market Revenue, by Cell Source (2017-2030)
- 21.4. Market Revenue, by Application (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Type (2017-2030)
- 22.3. Market Revenue, by Cell Source (2017-2030)
- 22.4. Market Revenue, by Application (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Type (2017-2030)
- 23.3. Market Revenue, by Cell Source (2017-2030)
- 23.4. Market Revenue, by Application (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Type (2017-2030)
- 24.3. Market Revenue, by Cell Source (2017-2030)
- 24.4. Market Revenue, by Application (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Type (2017-2030)
- 25.3. Market Revenue, by Cell Source (2017-2030)
- 25.4. Market Revenue, by Application (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Type (2017-2030)
- 26.3. Market Revenue, by Cell Source (2017-2030)
- 26.4. Market Revenue, by Application (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Type (2017-2030)
- 27.3. Market Revenue, by Cell Source (2017-2030)
- 27.4. Market Revenue, by Application (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Type (2017-2030)
- 28.3. Market Revenue, by Cell Source (2017-2030)
- 28.4. Market Revenue, by Application (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Smith & Nephew plc
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. MEDIPOST Co. Ltd.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Anterogen Co. Ltd.
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. CORESTEM Inc.
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. PHARMICELL Co. Ltd.
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. NuVasive Inc.
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. RTI Surgical Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. AlloSource
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. JCR Pharmaceutical Co. Ltd.
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
- 30.10. Takeda Pharmaceutical Company Limited
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
